SANUWAVE Health, Inc.
Close on Oct 19, 2026
- Market cap
- $41.54M
- P/E (TTM)
- 11.8
- Dividend yield
- –
Earnings
Next report expected Nov 6, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | $9.70M | $-0.08 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | After market close | $9.60M | $-0.17 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | After market close | $13.40M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 7, 2025 | Before market open | $11.50M | $0.46 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 14, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 8, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 14, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 8, 2024 | Before market open | $9.40M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 10, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 10, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 10, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on May 12, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| revenue | Q2 2026 | $11.10M to $11.60M | New |
| revenue guidance | full year 2026 | $51.00M to $55.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements SANUWAVE Health filed with the SEC
Sanuwave Announces Q2 FY2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6–$9.8 Million, Above High End of Revised Guidance
Results of operations · EX-99.1 to Form 8-K
Sanuwave Health Updates Second Quarter 2026 Guidance
Regulation FD disclosure · EX-99.1 to Form 8-K
Sanuwave Announces Revenues and Financial Results for Q1 FY2026
Results of operations · EX-99.1 to Form 8-K
Sanuwave Health Reports Preliminary Q1 2026 Revenue of $9.6–$9.7 Million, Up 3-4% Year-over-Year
Results of operations · EX-99.1 to Form 8-K
Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025
Results of operations · EX-99.1 to Form 8-K
Sanuwave Announces Q3 FY2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Sanuwave Announces Strategic Debt Refinancing with New Credit Facility
Material agreement · Agreement terminated · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Sanuwave Announces Q2 FY2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
SANUWAVE Health Announces Preliminary Revenue Results for the Second Quarter 2025 (Ended June 30, 2025)
Results of operations · EX-99.1 to Form 8-K
Sanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial Operations
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Sanuwave Announces Q1 FY2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025)
Results of operations · EX-99.1 to Form 8-K
SANUWAVE Announces Record Quarterly Revenues: Q4 FY2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Sanuwave Health to Uplist to the Nasdaq Global Market
Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
SANUWAVE Announces Preliminary Revenue Results for the Fourth Quarter 2024 (Ended December 31, 2024)
Results of operations · EX-99 to Form 8-K
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Sanuwave Health Announces 1-For-375 Reverse Stock Split
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
SANUWAVE Announces Record Quarterly Revenues: Q2 FY2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
SANUWAVE Health Announces Preliminary Revenue Results for the Second Quarter 2024 (Ended June 30, 2024)
Results of operations · EX-99.1 to Form 8-K
Sanuwave Announces Termination of Merger Agreement with SEP Acquisition Corp.
Agreement terminated · Regulation FD disclosure · EX-99.1 to Form 8-K
Sanuwave pays off $6.3 million Celularity note and interest for $2.075 million
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
SANUWAVE Announces Q1 FY2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2024 (Ended March 31, 2024)
Results of operations · EX-99.1 to Form 8-K
SANUWAVE Health Appoints Industry Veteran Peter Sorensen as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
SANUWAVE Announces Record Q4 and FY2023 Revenue
Results of operations · EX-99.1 to Form 8-K
SANUWAVE Health Announces Preliminary Revenue Results for the Fourth Quarter and Fiscal Year 2023, Ended December 31,
Results of operations · EX-99.1 to Form 8-K
SANUWAVE Announces Q3 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
SANUWAVE Health Announces Preliminary Revenue Results for the Third Quarter Ended September 30, 2023
Results of operations · EX-99.1 to Form 8-K
This presentation (“Presentation”) is for informational purposes only to
Regulation FD disclosure · EX-99.1 to Form 8-K
SANUWAVE Health, Inc., a Leading Provider of FDA Approved Next-Generation Wound Care Products, Enters into a Merger Agreement with Sweat Equity
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
SANUWAVE Announces Q2 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
SANUWAVE Health Appoints Industry Veteran Andrew Walko as President
Executive or director change · Regulation FD disclosure · EX-99 to Form 8-K
SANUWAVE Health Announces Preliminary Revenue Results for the Second Quarter Ended June 30, 2023
Results of operations · EX-99.1 to Form 8-K
SANUWAVE Health, Inc. Appoints Morgan Frank as Chief
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Sanuwave announces Q1 2023 financial results
Results of operations · EX-99.1 to Form 8-K
SANUWAVE Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
SANUWAVE HEALTH REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS & WILL HOST LIVE CONFERENCE CALL WITH BUSINESS UPDATE
Results of operations · EX-99.2 to Form 8-K